Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barratt Redrow COO retires after 47 years with the company

(Sharecast News) - Housebuilder Barratt Redrow has announced that its chief operating officer and deputy CEO, Steven Boyes, is planning on retiring later this year - after nearly five decades of service. Boyes, who joined Barratt in 1978, has informed the board that he intends to retire, and will leave the company on 6 September.

Having started as a junior quantity surveyor, he progressed to become technical director and managing director of Barratt York, before being appointed as regional director for Barratt Northern in 1999.

He then joined the board as a regional chairman and executive director in 2001, became COO in 2012 and deputy CEO in 2016.

These days, Boyes is in charge of Barratt Redrow's housebuilding operations, the timber frame manufacturing business, Oregon, and group land activity and the land promotion business, Gladman.

Chair Caroline Silver thanked Boyes for his "outstanding contribution" to the firm over the past 47 years. "Steven has been instrumental in delivering our strong track record on build quality, sustainability and innovation - which are so fundamental to the hundreds of thousands of high-quality homes we have built for customers across the country," she said.

Boyes will step down as a director in September, but be available to the company for another six months after that.

Barratt Redrow's share price was up 1.6% at 422.39p by 1327 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.